Microbiome Therapeutics Market Revenues To Double By 2030 - Key Opportunities Lie In Live-Biotherapeutics, Personalized Medicine, And Digital Health Integrations

(MENAFN- GlobeNewsWire - Nasdaq) The microbiome therapeutics market thrives on innovation, strategic partnerships, and regulatory adaptation. Expanding applications from neurology to oncology promise growth, while resilient supply chains support global expansion.

Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics Market by Products (Fecal Microbiota Transplantation, Live-Biotherapeutics, Microbiome Drugs), Therapeutic Area (Autoimmune Diseases, Cancer, Gastrointestinal Disorders), Formulation, Source, End-use, Distribution Channel - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering.

The microbiome therapeutics market is undergoing accelerated change as scientific advancements and new clinical applications foster a competitive environment for innovative healthcare solutions. Industry leadership now depends on integrating cross-disciplinary expertise, strategic partnerships, and rigorous market assessment to navigate emerging challenges and capture untapped potential in this expanding field.

Market Snapshot: Microbiome Therapeutics Market Overview

The Microbiome Therapeutics Market grew from USD 1.11 billion in 2024 to USD 1.27 billion in 2025. It is expected to continue growing at a CAGR of 14.65%, reaching USD 2.54 billion by 2030. This growth is fueled by innovation in live-biotherapeutics, rapid developments in genomics, and expanding applications across multiple disease indications. As new trade measures, regulatory frameworks, and global partnerships evolve, business leaders are seeking actionable insights and comprehensive analysis to make informed strategic decisions in this dynamic sector.

Scope & Segmentation

This report provides a detailed exploration of the microbiome therapeutics market, spanning a diverse array of products, therapeutic areas, formulations, sources, end-users, and distribution models. Each segment presents distinct growth opportunities and operational considerations.

Key Takeaways for Senior Decision-Makers

• Advances in analytical technologies and bioinformatics are supporting the development of more targeted and multifaceted microbiome-based therapies, enabling creative therapeutic approaches that move beyond traditional probiotics and prebiotics.
• Industry collaborations, especially between academic centers and biotech firms, are accelerating product innovation, validation, and translation from research to market, enabling personalized approaches and faster adoption.
• Adaptation to evolving regulatory frameworks is essential, with organizations increasingly investing in compliance expertise and early dialogue to ensure smooth product progression and access in diverse jurisdictions.
• Manufacturing strategies are shifting toward resilience and geographic diversification, as firms seek to address supply chain disruption risks and support sustainable global expansion.
• Digital health integrations-such as remote monitoring, data-driven patient engagement, and telemedicine-enhance trial efficiency, evidence generation, and patient adherence across regions.
• Expanding therapeutic indications highlight the versatility and scalability of microbiome interventions in areas ranging from neurology to oncology, positioning organizations to capture value across new clinical frontiers.

Tariff Impact: Navigating Trade Barriers and Industry Resilience

Recent tariff policies and trade adjustments have added complexity to supply chains, directly impacting sourcing costs for microbial strains, reagents, and specialized materials. Clinical operations have seen rising input costs, prompting organizations to evaluate strategies such as nearshoring, supply diversification, and domestic manufacturing investments. Legal and compliance teams must navigate intricate tariff classifications, as these trade measures often affect project timelines and budget planning. While present challenges may initially raise operational hurdles, they are fostering the emergence of more resilient and regionally distributed production ecosystems.

Methodology & Data Sources

The findings in this report combine in-depth primary research, including expert interviews and real-world stakeholder insights, with secondary analysis of academic publications, corporate filings, and regulatory documents. Key data are cross-verified using triangulation, market mapping, scenario planning, and competitiveness assessment to ensure objectivity, transparency, and actionable recommendations.

Why This Report Matters for Strategic Leadership

• Equips senior leaders and market strategists with data-driven insights to guide investment, portfolio planning, and market entry.
• Enables organizations to anticipate regulatory and trade shifts, fortify supply chains, and optimize competitive positioning in a changing landscape.
• Supports proactive decision-making by detailing innovative pipelines, cross-sector partnerships, and commercial strategies tailored to evolving global opportunities.

Key Attributes

Report Attribute	Details
No. of Pages	189
Forecast Period	2025 - 2030
Estimated Market Value (USD) in 2025	$1.27 Billion
Forecasted Market Value (USD) by 2030	$2.54 Billion
Compound Annual Growth Rate	14.6%
Regions Covered	Global

Key Topics Covered
1. Preface
2. Research Methodology
3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in targeted CRISPR-based microbiome editing for precision gut flora modulation
5.2. Rising investment in anaerobic spore-based therapeutics for recurrent Clostridioides difficile prevention
5.3. Development of live biotherapeutic consortiums to treat inflammatory bowel disease with defined microbial strains
5.4. Integration of multi-omics data and machine learning to identify personalized microbial biomarkers
5.5. Emergence of postbiotic and paraprobiotic formulations as stable alternatives to live microbial therapies
5.6. Evolving regulatory frameworks by FDA and EMA to accelerate approval of microbiome-based drugs
5.7. Strategic alliances between biotech innovators and pharmaceutical giants to commercialize next-generation microbiome therapies
6. Market Insights
6.1. Porter's Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025

8. Microbiome Therapeutics Market, by Products
8.1. Introduction
8.2. Fecal Microbiota Transplantation
8.3. Live-Biotherapeutics
8.4. Microbiome Drugs
8.5. Microbiome Ecosystem Therapies
8.6. Probiotics & Prebiotics
9. Microbiome Therapeutics Market, by Therapeutic Area
9.1. Introduction
9.2. Autoimmune Diseases
9.3. Cancer
9.4. Gastrointestinal Disorders
9.5. Infectious Diseases
9.6. Metabolic Disorders
9.7. Neurological Disorders
10. Microbiome Therapeutics Market, by Formulation
10.1. Introduction
10.2. Oral
10.3. Topical
11. Microbiome Therapeutics Market, by Source
11.1. Introduction
11.2. Animal Microbiome
11.3. Environmental Microbiome
11.4. Human Microbiome
12. Microbiome Therapeutics Market, by End-use
12.1. Introduction
12.2. Academic & Research Institutions
12.3. Hospitals & Clinics
13. Microbiome Therapeutics Market, by Distribution Channel
13.1. Introduction
13.2. Offline
13.2.1. Hospital Pharmacies
13.2.2. Retail Pharmacies
13.3. Online Pharmacies
14. Americas Microbiome Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Microbiome Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Microbiome Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Alveolus Bio, Inc. by ResBiotic
17.3.2. AOBiome LLC
17.3.3. Assembly Biosciences, Inc.
17.3.4. Axial Therapeutics, Inc.
17.3.5. BioGaia AB
17.3.6. BiomeBank
17.3.7. EnteroBiotix Ltd
17.3.8. Enterome SA
17.3.9. Ferring B.V.
17.3.10. Intralytix, Inc.
17.3.11. Kanvas Biosciences
17.3.12. Locus Biosciences, Inc.
17.3.13. MaaT Pharma SA
17.3.14. Microba Life Sciences Limited
17.3.15. Microbiotica Ltd.
17.3.16. MRM Health NV
17.3.17. NuBiyota
17.3.18. Osel, Inc.
17.3.19. Pendulum Therapeutics
17.3.20. PharmaBiome AG
17.3.21. Pylum Biosciences
17.3.22. Seres Therapeutics, Inc.
17.3.23. Servatus Limited
17.3.24. Siolta Therapeutics
17.3.25. Theriva Biologics, Inc.
17.3.26. Vedanta Biosciences, Inc.
17.3.27. Viome Life Sciences, Inc. by BlueDot LLC
17.3.28. Xbiome Co. Ltd.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Microbiome Therapeutics Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN02092025004107003653ID1110004712